{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:39:40Z","timestamp":1792604380721,"version":"4.5.0"},"reference-count":26,"publisher":"MyJove Corporation","issue":"206","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/66785","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T20:00:22Z","timestamp":1713556822000},"source":"Crossref","is-referenced-by-count":4,"title":["Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes"],"prefix":"10.3791","author":[{"given":"Sarah","family":"Poirier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jean-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jpids\/piac061","type":"journal-article","article-title":"Drugs, drugs, drugs: Current treatment paradigms in cystic fibrosis airway infections","volume":"11","author":"Cogen","year":"2022","unstructured":"Cogen, J. D., Nichols, D. P., Goss, C. H., Somayaji, R. Drugs, drugs, drugs: Current treatment paradigms in cystic fibrosis airway infections. J Pediatric Infect Dis Soc. 11 (2), S32-S39 (2022).","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"9678","key":"ref2","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","type":"journal-article","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","unstructured":"O'Sullivan, B. P. Freedman, S. D. Cystic fibrosis. Lancet. 373 (9678), 1891-1904 (2009).","journal-title":"Lancet"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"e00006","DOI":"10.1128\/mBio.00006-21","type":"journal-article","article-title":"One versus many: Polymicrobial communities and the cystic fibrosis airway","volume":"12","author":"Jean-Pierre","year":"2021","unstructured":"Jean-Pierre, F., Vyas, A., Hampton, T. H., Henson, M. A., O'Toole, G. A. One versus many: Polymicrobial communities and the cystic fibrosis airway. mBio. 12 (2), e00006-00021 (2021).","journal-title":"mBio"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12931-023-02630-z","type":"journal-article","article-title":"Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after elexacaftor-tezacaftor-ivacaftor therapy","volume":"24","author":"Martin","year":"2023","unstructured":"Martin, C. et al. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after elexacaftor-tezacaftor-ivacaftor therapy. Respir Res. 24 (1), 317 (2023).","journal-title":"Respir Res"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","type":"journal-article","article-title":"A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","unstructured":"Sosinski, L. M. et al. A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung. J Cystic Fibros. 21 (6), 996 Respiratory Research. 1005 (2022).","journal-title":"J Cystic Fibros"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"e00530","DOI":"10.1128\/JB.00530-19","type":"journal-article","article-title":"34;It takes a village": Mechanisms underlying antimicrobial recalcitrance of polymicrobial biofilms","volume":"202","author":"Orazi","year":"2019","unstructured":"Orazi, G. O'Toole, G. A. \"It takes a village\": Mechanisms underlying antimicrobial recalcitrance of polymicrobial biofilms. J Bacteriol. 202 (1), e00530-00619 (2019).","journal-title":"J Bacteriol"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","type":"journal-article","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial","volume":"205","author":"Nichols","year":"2022","unstructured":"Nichols, D. P. et al. Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: A clinical trial. Am J Respir Crit Care Med. 205 (5), 529-539 (2022).","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"e1005258","DOI":"10.1371\/journal.ppat.1005258","type":"journal-article","article-title":"Cystic fibrosis lung infections: Polymicrobial, complex, and hard to treat","volume":"11","author":"Filkins","year":"2015","unstructured":"Filkins, L. M. O'Toole, G. A. Cystic fibrosis lung infections: Polymicrobial, complex, and hard to treat. PLoS Pathog. 11 (12), e1005258 (2015).","journal-title":"PLoS Pathog"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10096-016-2621-0","type":"journal-article","article-title":"Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes","volume":"35","author":"Limoli","year":"2016","unstructured":"Limoli, D. H. et al. Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes. Eur J Clin Microbiol Infect Dis. 35 (6), 947-953 (2016).","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"e81604","DOI":"10.7554\/eLife.81604","type":"journal-article","article-title":"Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system","volume":"12","author":"Jean-Pierre","year":"2023","unstructured":"Jean-Pierre, F. et al. Community composition shapes microbial-specific phenotypes in a cystic fibrosis polymicrobial model system. Elife. 12 (12), e81604 (2023).","journal-title":"Elife"},{"issue":"4","key":"ref11","first-page":"e00873","type":"journal-article","article-title":"Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection","volume":"8","author":"Toole Orazi","year":"2017","unstructured":"Orazi, G. O'Toole, G. A. Pseudomonas aeruginosa alters Staphylococcus aureus sensitivity to vancomycin in a biofilm model of cystic fibrosis infection. mBio. 8 (4), e00873-00917 (2017).","journal-title":"mBio"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1093\/jpids\/piac040","type":"journal-article","article-title":"The sense and nonsense of antimicrobial susceptibility testing in cystic fibrosis","volume":"11","author":"Lipuma","year":"2022","unstructured":"Lipuma, J. J. The sense and nonsense of antimicrobial susceptibility testing in cystic fibrosis. J Pediatric Infect Dis Soc. 11 (2), S46-S52 (2022).","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"e0002423","DOI":"10.1128\/cmr.00024-23","type":"journal-article","article-title":"Biofilm antimicrobial susceptibility testing: Where are we and where could we be going","volume":"36","author":"Coenye","year":"2023","unstructured":"Coenye, T. Biofilm antimicrobial susceptibility testing: Where are we and where could we be going? Clin Microbiol Rev. 36 (4), e0002423 (2023).","journal-title":"Clin Microbiol Rev"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciz364","type":"journal-article","article-title":"Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections","volume":"69","author":"Waters","year":"2019","unstructured":"Waters, V. J. et al. Reconciling antimicrobial susceptibility testing and clinical response in antimicrobial treatment of chronic cystic fibrosis lung infections. Clin Infect Dis. 69 (10), 1812-1816 (2019).","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"100031","DOI":"10.1016\/j.bioflm.2020.100031","type":"journal-article","article-title":"Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm","volume":"2","author":"Vandeplassche","year":"2020","unstructured":"Vandeplassche, E. et al. Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm. Biofilm. 2, 100031 (2020).","journal-title":"Biofilm"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"e0031822","DOI":"10.1128\/msphere.00318-22","type":"journal-article","article-title":"Antibiotics drive expansion of rare pathogens in a chronic infection microbiome model","volume":"7","author":"Varga","year":"2022","unstructured":"Varga, J. J. et al. Antibiotics drive expansion of rare pathogens in a chronic infection microbiome model. mSphere. 7 (5), e0031822 (2022).","journal-title":"mSphere"},{"issue":"13","key":"ref17","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1073\/pnas.1419677112","type":"journal-article","article-title":"Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum","volume":"112","author":"Turner","year":"2015","unstructured":"Turner, K. H., Wessel, A. K., Palmer, G. C., Murray, J. L., Whiteley, M. Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum. Proc Natl Acad Sci U S A. 112 (13), 4110-4115 (2015).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1073\/pnas.1917576117","type":"journal-article","article-title":"Pseudomonas aeruginosa lasR mutant fitness in microoxia is supported by an anr-regulated oxygen-binding hemerythrin","volume":"117","author":"Clay","year":"2020","unstructured":"Clay, M. E. et al. Pseudomonas aeruginosa lasR mutant fitness in microoxia is supported by an anr-regulated oxygen-binding hemerythrin. Proc Natl Acad Sci U S A. 117 (6), 3167-3173 (2020).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcf.2008.09.006","type":"journal-article","article-title":"Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression","volume":"8","author":"Hoffman","year":"2009","unstructured":"Hoffman, L. R. et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros. 8 (1), 66-70 (2009).","journal-title":"J Cyst Fibros"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/thoraxjnl-2019-214191","type":"journal-article","article-title":"Sputum microbiota in adults with CF associates with response to inhaled tobramycin","volume":"75","author":"Heirali","year":"2020","unstructured":"Heirali, A. et al. Sputum microbiota in adults with CF associates with response to inhaled tobramycin. Thorax. 75 (12), 1058-1064 (2020).","journal-title":"Thorax"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/thoraxjnl-2019-214187","type":"journal-article","article-title":"Maintenance tobramycin primarily affects untargeted bacteria in the cf sputum microbiome","volume":"75","author":"Nelson","year":"2020","unstructured":"Nelson, M. T. et al. Maintenance tobramycin primarily affects untargeted bacteria in the cf sputum microbiome. Thorax. 75 (9), 780-790 (2020).","journal-title":"Thorax"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"e0220123","DOI":"10.1128\/spectrum.02201-23","type":"journal-article","article-title":"Transcriptional profiling and genetic analysis of a cystic fibrosis airway-relevant model shows asymmetric responses to growth in a polymicrobial community","volume":"11","author":"Kesthely","year":"2023","unstructured":"Kesthely, C. A., Rogers, R. R., El Hafi, B., Jean-Pierre, F., O'Toole, G. A. Transcriptional profiling and genetic analysis of a cystic fibrosis airway-relevant model shows asymmetric responses to growth in a polymicrobial community. Microbiol Spectr. 11 (5), e0220123 (2023).","journal-title":"Microbiol Spectr"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"634479","DOI":"10.3389\/fmolb.2021.634479","type":"journal-article","article-title":"Metabolic modeling to interrogate microbial disease: A tale for experimentalists","volume":"8","author":"Jean-Pierre","year":"2021","unstructured":"Jean-Pierre, F., Henson, M. A., O'Toole, G. A. Metabolic modeling to interrogate microbial disease: A tale for experimentalists. Front Mol Biosci. 8, 634479 (2021).","journal-title":"Front Mol Biosci"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1073\/pnas.1516979113","type":"journal-article","article-title":"Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity","volume":"113","author":"Hendricks","year":"2016","unstructured":"Hendricks, M. R. et al. Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity. Proc Natl Acad Sci U S A. 113 (6), 1642-1647 (2016).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1365-2958.2004.04349.x","type":"journal-article","article-title":"A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology","volume":"54","author":"Hogan","year":"2004","unstructured":"Hogan, D. A., Vik, A., Kolter, R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol. 54 (5), 1212-1223 (2004).","journal-title":"Mol Microbiol"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.matt.2023.10.029","type":"journal-article","article-title":"Co-assembling living material as an in vitro lung epithelial infection model","volume":"7","author":"Wu","year":"2024","unstructured":"Wu, Y. et al. Co-assembling living material as an in vitro lung epithelial infection model. Matter. 7 (1), 216-236 (2024).","journal-title":"Matter"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jove.com\/t\/66785\/growing-cystic-fibrosis-relevant-polymicrobial-biofilm-to-probe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:02:38Z","timestamp":1792602158000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/66785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":26,"journal-issue":{"issue":"206","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3791\/66785","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.01.26.577445","asserted-by":"object"}]},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}